Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12635692 | 0.85 | TDP1 (0.44) | TDP1MAOAMAOBKMT2AMEN1 | |
| SCHEMBL17696576 | 0.83 | TDP1 (0.43) | TDP1MAOAMAOBKMT2AMEN1 | |
| SCHEMBL6195253 | 0.81 | TDP1 (0.50) | TDP1MAOAMAOBKMT2AMEN1 | |
| SCHEMBL18618701 | 0.80 | TDP1 (0.47) | TDP1MAOAMAOBKMT2AMEN1 | |
| SCHEMBL3677388 | 0.80 | TDP1 (0.47) | TDP1MAOAMAOBKMT2AMEN1 | |
| SCHEMBL6193192 | 0.79 | TDP1 (0.56) | TDP1MAOAMAOBKMT2AMEN1 | |
| SCHEMBL1394865 | 0.78 | MAOA (0.51) | TDP1MAOAMAOBKMT2AMEN1 | |
| SCHEMBL13977596 | 0.78 | TDP1 (0.46) | TDP1MAOAMAOBKMT2AMEN1 | |
| SCHEMBL292627 | 0.78 | TDP1 (0.48) | TDP1MAOAMAOBKMT2AMEN1 | |
| SCHEMBL4714065 | 0.77 | TDP1 (0.52) | TDP1MAOAMAOBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9428528-B2 | Phenicol antibacterials | ZOETIS SERVICES LLC (US) | 2016-08-30 | — | — | US | disclosed |
| US-20160194342-A1 | PHENICOL ANTIBACTERIALS | ZOETIS SERVICES LLC (US) | 2016-07-07 | — | — | US | disclosed |
| US-9340564-B2 | Phenicol antibacterials | ZOETIS SERVICES LLC (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150266910-A1 | PHENICOL ANTIBACTERIALS | ZOETIS SERVICES LLC (US) | 2015-09-24 | — | — | US | disclosed |
| EP-2613785-B1 | HETEROARYLMETHYL AMIDES | HOFFMANN LA ROCHE (CH) | 2015-07-29 | — | — | EP | disclosed |
| US-9090599-B2 | Heteroarylmethyl amides | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9073894-B2 | Phenicol antibacterials | ZOETIS SERVICES LLC (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2822934-A1 | PHENICOL ANTIBACTERIALS | Zoetis LLC (US) | 2015-01-14 | — | — | EP | disclosed |
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | HOFFMANN-LA ROCHE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8729105-B2 | Heteroarylmethyl amides | HOFFMANN LA-ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| EP-1487828-B1 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008049747-A1 | NOVEL HETEROARYL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-02 | — | — | WO | disclosed |
| US-20080103143-A1 | NOVEL HETEROARYL CARBOXAMIDES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
| EP-1838706-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | Prosidion Limited (GB) | 2007-10-03 | — | — | EP | disclosed |
| EP-1711491-A1 | HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS | Prosidion Limited (GB) | 2006-10-18 | — | — | EP | disclosed |
| WO-2006067532-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LTD (GB) | 2006-06-29 | — | — | WO | disclosed |
| US-20060063765-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-03-23 | — | — | US | disclosed |
| WO-2005061489-A1 | HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2005-07-07 | — | — | WO | disclosed |
| EP-1487828-A2 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003082861-A2 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | TDP1 1579/4885MAOA 944/4885MAOB 1358/4885 |
| US-20160194342-A1 | PHENICOL ANTIBACTERIALS | MRPL21, TTL, CTSL | TDP1 3526/4885MAOA 2460/4885MAOB 2960/4885 |
| US-20080103143-A1 | NOVEL HETEROARYL CARBOXAMIDES | F12, F11, F2 | TDP1 2675/4885MAOA 377/4885MAOB 419/4885 |
| US-20060063765-A1 | Novel compounds | CCR3, NSUN3, CCR1 | TDP1 2438/4885MAOA 4538/4885MAOB 2263/4885 |
| US-20150266910-A1 | PHENICOL ANTIBACTERIALS | MRPL21, TTL, CTSL | TDP1 3526/4885MAOA 2460/4885MAOB 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.